What is Allogene Therapeutics's shares (basic)?

Allogene Therapeutics (ALLO) reported shares (basic) of 240.3M in Q1 2026.

How has Allogene Therapeutics's shares (basic) changed year-over-year?

Allogene Therapeutics's shares (basic) increased by 11.6% year-over-year, from 215.4M to 240.3M.

What is the long-term trend for Allogene Therapeutics's shares (basic)?

Over 4 years (2021 to 2025), Allogene Therapeutics's shares (basic) has grown at a 12.9% compound annual growth rate (CAGR), from 539.8M to 876.9M.

What does shares (basic) mean?

The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.

Allogene Therapeutics ALLO Shares (Basic)

Shares (Basic) at other companies

Gilead SciencesGILD

1.2B-0.3%

PrecigenPGEN

354.3M+20.6%

CRISPR TherapeuticsCRSP

96.1M+11.8%

Sana BiotechnologySANA

276.9M+16.5%

CytomX TherapeuticsCTMX

177.3M+103%

Immix Biopharma, Inc.IMMX

55.4M+86.4%

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's shares (basic)?: Allogene Therapeutics (ALLO) reported shares (basic) of 240.3M in Q1 2026.
How has Allogene Therapeutics's shares (basic) changed year-over-year?: Allogene Therapeutics's shares (basic) increased by 11.6% year-over-year, from 215.4M to 240.3M.
What is the long-term trend for Allogene Therapeutics's shares (basic)?: Over 4 years (2021 to 2025), Allogene Therapeutics's shares (basic) has grown at a 12.9% compound annual growth rate (CAGR), from 539.8M to 876.9M.
What does shares (basic) mean?: The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.